


Welcome to the Oncopeptides clinical development program.
Here, you will find an overview of our trial pipeline
and a brief review of each study.

STUDY TIMELINE



O-12-M1 Study

A Phase 1/2a study of melphalan flufenamide in combination with dexamethasone in adult patients with relapsed refractory multiple myeloma (RRMM) (O-12-M1)

HORIZON Study

A Phase 2 study of melphalan flufenamide in combination with dexamethasone in adult patients with relapsed refractory multiple myeloma (RRMM) that is refractory to pomalidomide and/or an anti-CD38 monoclonal antibody (OP-106 HORIZON)

OCEAN Study

A Phase 3 study of melphalan flufenamide in combination with dexamethasone versus pomalidomide in combination with dexamethasone in adult patients with relapsed refractory multiple myeloma (RRMM) that is refractory to lenalidomide (OP-103 OCEAN)

ANCHOR Study

A Phase 1/2a study of melphalan flufenamide in combination with dexamethasone and either bortezomib or daratumumab in adult patients with relapsed refractory multiple myeloma (RRMM) (OP-104 ANCHOR)

BRIDGE Study

A Phase 2 pharmacokinetics study of melphalan flufenamide in combination with dexamethasone in adult patients with relapsed refractory multiple myeloma (RRMM) and impaired renal function (OP-107 BRIDGE)

ASCENT Study

A Phase 1/2 study of melphalan flufenamide in combination with dexamethasone in adult patients with immunoglobulin light chain (AL) amyloidosis following at least 1 prior line of therapy (OP-201 ASCENT)

LIGHTHOUSE Study

A Phase 3 study of melphalan flufenamide in combination with dexamethasone and subcutaneous daratumumab versus subcutaneous daratumumab alone in adult patients with relapsed refractory multiple myeloma (RRMM) (OP-108 LIGHTHOUSE)

PORT Study

A Phase 2 pharmacokinetics study of melphalan flufenamide, administered by peripheral and central IV, in combination with dexamethasone in adult patients with relapsed refractory multiple myeloma (RRMM) (OP-109 PORT)

REFERENCES: 1. Our clinical studies. Oncopeptides. Accessed October 19, 2020. <https://oncopeptides.se/en/section/our-clinical-trials/> 2. Safety and efficacy of melflufen and dexamethasone in relapsed and/or relapsed-refractory multiple myeloma patients. ClinicalTrials.gov Identifier: NCT01897714. Updated August 24, 2020. Accessed October 19, 2020. <https://clinicaltrials.gov/ct2/show/NCT01897714> 3. A study of melphalan flufenamide (melflufen) in combination with dexamethasone in relapsed refractory multiple myeloma patients (HORIZON). ClinicalTrials.gov Identifier: NCT02963493. Updated July 7, 2020. Accessed October 19, 2020. <https://clinicaltrials.gov/ct2/show/NCT02963493> 4. A study of melphalan flufenamide (melflufen)-dex or pomalidomide-dex for RRMM patients refractory to lenalidomide (OCEAN). ClinicalTrials.gov Identifier: NCT03151811. Updated September 18, 2020. Accessed October 19, 2020. <https://clinicaltrials.gov/ct2/show/NCT03151811> 5. Study of melphalan flufenamide (melflufen) + dex with bortezomib or daratumumab in patients with RRMM (ANCHOR). ClinicalTrials.gov Identifier: NCT03481556. Updated April 10, 2020. Accessed October 19, 2020. <https://clinicaltrials.gov/ct2/show/NCT03481556> 6. A PK study of melphalan during treatment with melphalan flufenamide (melflufen) and dex in RRMM pat with impaired renal function. ClinicalTrials.gov Identifier: NCT03639610. Updated March 17, 2020. Accessed October 19, 2020. <https://clinicaltrials.gov/ct2/show/NCT03639610> 7. A clinical study of melphalan flufenamide (melflufen) and dexamethasone for patients with immunoglobulin light chain (AL) amyloidosis. ClinicalTrials.gov Identifier: NCT04115956. Updated August 27, 2020. Accessed October 19, 2020. <https://clinicaltrials.gov/ct2/show/NCT04115956> 8. Mateos M, Ocio EM, Sonneveld P, et al. LIGHTHOUSE (OP-108): a phase 3 study of melflufen in combination with daratumumab versus daratumumab in patients with relapsed/refractory multiple myeloma. Poster presented at: 25th Congress of the European Hematology Association (EHA); June 11-14, 2020; Virtual 9. A PK, safety and tolerability study of peripheral and central infusion of melflufen in RRMM patients (PORT). ClinicalTrials.gov Identifier: NCT04412707. Updated January 12, 2021. Accessed January 29, 2021. <https://clinicaltrials.gov/ct2/show/NCT04412707>